Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QDPR | P09417 | 3/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 5/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | CSF1R | P07333 | 1/20 | 0.36 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.36 |
| ▸ | WNT3A | P56704 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.32 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.32 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
| ▸ | CTSB | P07858 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7124582 | 1.00 | QDPR (0.40) | QDPRNAMPTHTR2CSIGMAR1ESR1 | |
| SCHEMBL7508337 | 0.76 | QDPR (0.39) | QDPRNAMPTWNT3A | |
| SCHEMBL7117906 | 0.76 | QDPR (0.39) | QDPRNAMPTWNT3A | |
| SCHEMBL7118426 | 0.76 | CCNT1 (0.39) | NAMPTWNT3A | |
| SCHEMBL7118665 | 0.76 | CCNT1 (0.39) | NAMPTWNT3A | |
| SCHEMBL8310327 | 0.76 | — | — | |
| SCHEMBL7126216 | 0.74 | NAMPT (0.49) | NAMPTWNT3ABRD4 | |
| SCHEMBL7126174 | 0.71 | QDPR (0.42) | QDPRNAMPTHTR2CSIGMAR1ESR1 | |
| SCHEMBL27374023 | 0.70 | QDPR (0.41) | QDPRNAMPTHTR2CSIGMAR1ESR1 | |
| SCHEMBL8451797 | 0.70 | MAPKAPK2 (0.39) | QDPRNAMPTHTR2CSIGMAR1ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030166684-A1 | 3-phenyl-furan-(5H)-2-one and dihydrofuran-2-one derivatives as antibacterial agents | SYNGENTA LIMITED (GB) | 2003-09-04 | — | — | US | disclosed |
| US-6110936-A | A BACTERICIDE TREATING A BACTERIAL INFECTION IN A WARM BLOODED ANIMAL | ZENECA LIMITED (GB) | 2000-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166684-A1 | 3-phenyl-furan-(5H)-2-one and dihydrofuran-2-one derivatives as antibacterial agents | CBR1, CBR3, CYP8B1 | QDPR 83/4885NAMPT 4578/4885HTR2C 370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.